ANPR-1 (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human Atrial Natriuretic Peptide Receptor 1 (NPR1/GC-A, UniProt P16066), expressed in HEK293 cells. Suitable for ligand-binding assays, guanylate cyclase activity measurements, inhibitor profiling, and antibody validation.
Expression system
HEK293
Cat. #
REC-ANPR1

In stock

SKU
REC-ANPR1
$498.00

Target Overview

ANPR-1 (Recombinant) is the human Atrial Natriuretic Peptide Receptor 1 (gene: NPR1; UniProt P16066), a 1,061-amino-acid single-pass transmembrane receptor that functions as a ligand-activated particulate guanylate cyclase (EC 4.6.1.2). This recombinant form is produced in HEK293 mammalian cells, providing the post-translational modifications — including N-linked glycosylation and appropriate disulfide bonding — that are critical for proper folding of the extracellular ligand-binding domain and catalytic intracellular cyclase domain. The protein serves as the primary signalling receptor for the natriuretic peptides ANP (NPPA) and BNP (NPPB). Ligand engagement drives conversion of GTP to cyclic guanosine monophosphate (cGMP), activating downstream PRKG1/PRKAA1-mediated pathways that regulate vascular tone and fluid volume. In the laboratory, this recombinant is used principally in three contexts. First, as an enzymatic reagent: the intracellular guanylate cyclase domain catalyses cGMP production measurable by ELISA or fluorescent reporter assays, enabling kinetic characterisation and inhibitor IC50 determination. Second, as a binding-assay component: the correctly folded extracellular domain supports surface plasmon resonance (SPR), biolayer interferometry (BLI), and competitive radioligand displacement experiments to quantify ANP/BNP affinity and screen peptide or small-molecule competitors. Third, as an antibody-validation standard: defined quantities of the recombinant protein provide a positive control for Western blot antibody titration. Researchers validating anti-NPR1 antibodies can pair this recombinant directly with the Triple Point Biologics matched antibody (SKU: RP-ANPR1), available as a cross-linked product on this site. The HEK293 expression system is preferred over prokaryotic hosts for this target because the receptor's extracellular domain contains multiple glycosylation sites whose occupancy influences ligand-binding kinetics in published assay formats.

Background

Atrial Natriuretic Peptide Receptor 1 (NPR1/ANPR-A/GC-A) is the principal membrane receptor mediating the cardiovascular and renal effects of the natriuretic peptide family. Structurally, it comprises an extracellular ligand-binding domain, a single transmembrane helix, a kinase homology domain (KHD) that acts as a regulatory switch, a dimerisation domain, and a C-terminal guanylate cyclase catalytic domain. In the unliganded state, the KHD suppresses cyclase activity; ANP or BNP binding induces a conformational change that relieves this inhibition and drives cGMP synthesis. NPR1 has been extensively characterised as a research target in the context of blood pressure regulation and cardiovascular homeostasis. Studies using NPR1 knockout and overexpression mouse models established that receptor-mediated cGMP signalling is required for normal natriuresis, diuresis, and systemic vascular resistance. Published biochemical work has mapped the receptor's homodimerisation interface and identified the ATP-binding site within the KHD as a regulatory locus sensitive to cellular energy state, findings that have guided the design of small-molecule probes used in mechanistic cell-biology studies. More recently, NPR1 has been investigated in the context of endothelial cell senescence and vascular aging. A 2022 study (PubMed: 36016499; cited in UniProt annotation for P16066) reported that NPR1 plays an essential role in regulating endothelial senescence through the ANP→cGMP→PRKG1→PRKAA1 axis, placing the receptor in research programmes examining age-related vascular dysfunction. Separately, a 2024 study (PubMed: 39543315) characterised NPR1's role in cardiovascular homeostasis at the molecular level, contributing to the mechanistic framework used to design NPR1-targeting tool compounds. In comparative endocrinology, NPR1 paralogs have been characterised across vertebrates. Okinishi et al. (2026) identified and performed neuroanatomical characterisation of an NPR1 paralog in the Japanese eel, demonstrating functional divergence from the mammalian receptor and providing an evolutionary context for structure-function studies of the natriuretic peptide receptor family. For researchers requiring an antibody alongside this recombinant, Triple Point Biologics has produced anti-NPR1 polyclonal antibodies since 1994; the matched reagent (SKU: RP-ANPR1) is validated for Western blot against human samples and is cross-linked from this product page. Using the recombinant as a spiked-in positive control alongside the antibody in the same Western blot run is a straightforward approach to confirm band identity at the expected molecular weight.

Applications

  • cGMP production activity assay: measure guanylate cyclase catalytic output by ELISA or fluorescent reporter upon ANP/BNP stimulation
  • Small-molecule and peptide inhibitor IC50 determination against the particulate guanylate cyclase domain
  • Ligand-binding affinity measurement (SPR or biolayer interferometry) for ANP, BNP, and competing peptide analogues
  • Competitive radioligand displacement assay to rank-order natriuretic peptide variants by receptor affinity
  • Antibody validation positive control for Western blot using matched Triple Point Biologics antibody RP-ANPR1
  • Kinase homology domain (KHD) conformational studies: ATP/ADP regulation of cyclase activity in biochemical reconstitution experiments
  • Cell-free receptor dimerisation assay to characterise interface-disrupting tool compounds by native PAGE or crosslinking mass spectrometry

References

  1. Okinishi R et al. Functional divergence of NPR1 paralog in the Japanese eel: Identification and neuroanatomical characterization. Gen Comp Endocrinol. 2026. doi:10.1016/j.ygcen.2026.114948. PMID: 42140325.

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Subcellular localization not yet annotated

Frequently Asked Questions

What is the expected molecular weight of recombinant ANPR-1 on SDS-PAGE and Western blot?

The unmodified polypeptide chain of human ANPR-1 (NPR1, 1,061 aa) predicts a molecular weight of approximately 119 kDa. Because this recombinant is produced in HEK293 cells, N-linked glycosylation adds roughly 15–25 kDa, so the predominant band typically migrates at 135–145 kDa under reducing SDS-PAGE conditions. Run a 6–8% polyacrylamide gel for clean resolution in this range. Under non-reducing conditions, aberrant migration is possible due to intact disulfide bonds in the extracellular domain. Always include a broad-range molecular weight ladder spanning 100–250 kDa.

Which isoform or processing form of ANPR-1 does the recombinant protein represent?

This recombinant corresponds to the canonical full-length human NPR1 isoform (UniProt P16066-1, residues 1–1,061), including the signal peptide, extracellular ligand-binding domain, single transmembrane segment, kinase homology domain, hinge region, and C-terminal guanylate cyclase catalytic domain. The signal peptide (residues 1–22) is processed co-translationally in HEK293 cells, so the mature secreted/membrane form begins at residue 23. No alternative splice isoforms with truncated cyclase domains are present in this preparation.

What substrate and assay format should I use to measure ANPR-1 guanylate cyclase activity in vitro?

ANPR-1 catalyses conversion of GTP to cyclic GMP (cGMP; EC 4.6.1.2). For in vitro activity assays, use 1 mM GTP as substrate in a reaction buffer of 50 mM Tris-HCl pH 7.5, 10 mM MgCl₂, 1 mM DTT, 0.5 mM IBMX (to inhibit phosphodiesterases). Quantify cGMP production with a competitive ELISA kit or HTRF cGMP assay after 30–60 min at 37 °C. A starting enzyme concentration of 50–200 nM recombinant ANPR-1 is recommended for initial titration. Verify activity is stimulated ≥3-fold by addition of 100 nM ANP (NPPA) ligand.

How should I optimize buffer conditions and ANP concentration for ANPR-1 activity assays?

The supplied storage buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol) is compatible with most activity assays after a simple dilution step. Dilute into assay buffer to reduce glycerol below 1% final concentration, as higher glycerol can suppress cGMP signal. Mg²⁺ is essential — confirm 5–10 mM MgCl₂ in the final reaction. For dose–response experiments, titrate synthetic ANP across 0.01–1,000 nM; reported EC₅₀ values for NPR1 activation by ANP fall in the 1–10 nM range. Include a vehicle-only (no ligand) baseline and a saturating ligand control in every experiment.

Can I use recombinant ANPR-1 as a positive control for Western blot with TPB antibody RP-ANPR1?

Yes — recombinant ANPR-1 (REC-ANPR1) is the validated positive control for the matched rabbit polyclonal antibody RP-ANPR1 (/anti-anpr-1-rabbit-polyclonal-antibody). Load 20–50 ng of recombinant protein per lane on a 6–8% SDS-PAGE gel under reducing conditions. The glycosylated band at 135–145 kDa should resolve cleanly with RP-ANPR1 at a primary antibody dilution of 1:500–1:2,000. Because REC-ANPR1 and RP-ANPR1 are produced in the same laboratory, lot-to-lot epitope compatibility is guaranteed, eliminating a common source of validation uncertainty.

How much recombinant ANPR-1 should I load for Western blot positive control to avoid signal saturation?

Start with a three-point titration: 10 ng, 25 ng, and 50 ng per lane. With RP-ANPR1 at 1:1,000 and a standard HRP-conjugated anti-rabbit secondary (1:5,000–1:10,000), 25 ng typically gives a clean, unsaturated band at 135–145 kDa on ECL detection with a 30–60 second exposure. If you are running the recombinant alongside cell lysate lanes, load the 10 ng point in the same blot to keep relative signal in a comparable range. Avoid loading >100 ng, which tends to produce a smeared high-MW artifact from aggregation.

How should I handle, dilute, and store recombinant ANPR-1 to maintain activity?

REC-ANPR1 is supplied as a ready-to-use solution in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol at >90% purity by SDS-PAGE and <0.1 EU/µg endotoxin (LAL). Store at −20 °C in single-use aliquots; repeated freeze-thaw cycles measurably reduce guanylate cyclase activity. When diluting for assays, use carrier protein (0.1% BSA) in the dilution buffer to minimize adsorptive losses at low concentrations (<10 nM). Working aliquots can be kept at 4 °C for up to 48 hours. Do not dilute into buffers below pH 6.5 or above pH 8.5.

Is recombinant ANPR-1 suitable for SPR or pull-down binding studies with ANP or BNP peptides?

Yes. Because REC-ANPR1 is produced in HEK293 cells, the extracellular ligand-binding domain carries native N-linked glycosylation and correct disulfide bonding, both of which are required for high-affinity natriuretic peptide binding. For SPR, immobilize REC-ANPR1 via amine coupling at 5–10 µg/mL in 10 mM sodium acetate pH 4.5, and flow ANP or BNP as analyte. Reported K_D values for ANP binding to NPR1 ECD are in the low nanomolar range (1–5 nM). For pull-down experiments, RP-ANPR1 (SKU: RP-ANPR1) can be used to confirm capture of the recombinant bait protein by Western blot.

Validation imagery coming soon

Western blot validation figures for REC-ANPR1 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →